-+ 0.00%
-+ 0.00%
-+ 0.00%

Rakovina Therapeutics to Present Preclinical ATR Inhibitor Data in PTEN-Deficient Prostate Cancer

PUBT·11/16/2026 10:30:27
Listen to the news
Rakovina Therapeutics to Present Preclinical ATR Inhibitor Data in PTEN-Deficient Prostate Cancer
  • Rakovina Therapeutics will present preclinical kt-5000AI prostate cancer data November 19, 2026, at the EORTC-NCI-AACR Symposium in Barcelona.
  • Previously reported findings showed potent, selective ATR inhibition with improved metabolic stability in optimized compounds.
  • Development now prioritizes brain-penetrant, ATR-selective compounds targeting PTEN-deficient tumors, while retaining opportunities to investigate combined ATR/mTOR inhibition.
  • The program remains preclinical, with lead optimization ongoing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rakovina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160530PRIMZONEFULLFEED9878139) on November 16, 2026, and is solely responsible for the information contained therein.